McKesson Applauds DOJ Policy Change on Opioid Quotas

16:19 EDT 12 Jul 2018 | Businesswire

McKesson Corporation

Company previously called for revisions to production quota

McKesson Corporation today praised the U.S. Department of Justice’s decision to exercise its authority to reduce opioid production if the agency believes a particular drug is highly diverted.

“We applaud this common-sense action by the Department of Justice. The annual opioid production quota determines the total amount of controlled substances that can be produced each year. That authority is significant as the nation struggles to address the current public health crisis around opioid addiction. This new rule calls on the Drug Enforcement Administration to carefully assess which drugs are being diverted – an important part of the effort to curb opioid misuse and abuse.”

In October 2017, McKesson called on the DEA to revise its annual production quota for opioids.

McKesson is deeply concerned by the impact the opioid epidemic is having on families and communities across the nation—and is committed to being part of the solution. The company has formed an independent foundation dedicated to addressing the crisis, to which McKesson contributed $100 million. The company is also advancingcompany initiativesaimed at preventing opioid abuse and has offered thoughtful public policy recommendations, including the Prescription Safety-Alert System (RxSAS) technology proposal.

To learn more about McKesson’s comprehensive efforts to address the opioid epidemic, please visit:

About McKesson Corporation

McKesson Corporation, currently ranked 5th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help make the right medicines, medical products and healthcare services available to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities that make our customers and partners more successful — all for the better health of patients. McKesson has been named the “Most Admired Company” in the healthcare wholesaler category by FORTUNE, a “Best Place to Work” by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly. For more information, visit

McKesson Corporation
April Marks, 415-732-1384


More From BioPortfolio on "McKesson Applauds DOJ Policy Change on Opioid Quotas"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...